Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01257568 · ClinicalTrials.gov registry record · NA
Rejuvenate Modular Outcomes Study
A NA study, sponsored by Stryker Orthopaedics.
- Completed
- Registry status
- NA
- Development phase
- 42
- Enrollment target
NCT01257568: Completed NA study, sponsored by Stryker Orthopaedics.
NCT01257568 is a NA study that has completed, run by Stryker Orthopaedics. The registered enrollment target is 42 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01257568, a NA study, has completed, sponsored by Stryker Orthopaedics.
- COMPLETED
- Registry status
- NA
- Development phase
- 42 participants
- Enrollment target
Study Summary
This study will be an evaluation of the Rejuvenate® Modular Hip System for primary total hip replacement (THR) with a cementless application in a consecutive series of patients who meet the eligibility criteria. Subjects will be evaluated for freedom of hip revision at 5 years and clinical outcomes for up to 10 years after surgery.
Primary Outcome
The success rate is defined as freedom from Rejuvenate Modular femoral stem/neck construct revision/removal for any reason.
Interventions
- DEVICE Rejuvenate Modular Hip
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2010-11 |
| Est. Completion | 2022-01-20 |
| Phase | NA |
What the finished NCT01257568 record still lists
NCT01257568 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Rejuvenate Modular Hip is the first listed.
NCT01257568 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01257568 about?
NCT01257568 is a clinical study titled "Rejuvenate Modular Outcomes Study". This study will be an evaluation of the Rejuvenate® Modular Hip System for primary total hip replacement (THR) with a cementless application in a consecutive series of patients who meet the eligibility criteria. Subjects will be evaluated for freedom of hip revision at 5 years and clinical outcomes ...
What is the current status of trial NCT01257568?
This trial is currently completed. It is a NA study. The enrollment target is 42 participants. The study started on 2010-11. Estimated completion is 2022-01-20.
What interventions are being tested in trial NCT01257568?
The interventions under investigation include: Rejuvenate Modular Hip (DEVICE).
Who is sponsoring clinical trial NCT01257568?
This trial is sponsored by Stryker Orthopaedics, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01257568's enrollment target sits among peer trials
42 1436th of 2000 higher than 555 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia